Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma

Medical Hypotheses

Volumn 93, Issue , 2016, Pages 74-76

  Kubecek, Ondrej ^a   Trojanova, Petronela ^a   Molnarova, Veronika ^a   Kopecky, Jindrich ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; MICROSATELLITE DNA; TUMOR ANTIGEN;

ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; COLORECTAL CANCER; DNA REPAIR; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPHOCYTE FUNCTION; MELANOMA; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; PHENOTYPE; SOMATIC MUTATION; TREATMENT RESPONSE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; PROCEDURES; PROGNOSIS; SKIN NEOPLASMS; T LYMPHOCYTE; THEORETICAL MODEL;

ANTIGENS, NEOPLASM; DNA REPAIR; HUMANS; IMMUNOTHERAPY; MELANOMA; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MODELS, THEORETICAL; MUTATION; PROGNOSIS; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 84969749387     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.05.023     Document Type: Article

References (39)

1. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58(22):5248-5257.
2. Champiat S., Ferté C., Lebel-Binay S., Eggermont A., Soria J.C. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014, 3(1):e27817.
3. Banerjea A., Ahmed S., Hands R.E., et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased imunogenicity. Mol Cancer 2004, 3:21.
4. Saeterdal I., Gjertsen M.K., Straten P., Eriksen J.A., Gaudernack G. A TGF betaRII frameshift-mutation-derived CTL epitope recognized by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother 2001, 50(9):469-476.
5. Saeterdal I., Bjorheim J., Lislerud K., et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001, 98(23):13255-13260.
6. Bauer K., Nelius N., Reuschenbach M., et al. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother 2013, 62(1):27-37.
7. Nosho K., Baba Y., Tanaka N., Shima K., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010, 222(4):350-366.
8. Boissière-Michot F., Lazennec G., Frugier H., et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology 2014, 3:e29256.
9. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
10. Le Gouvello S., Bastuji-Garin S., Aloulou N., et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57(6):772-779.
11. Llosa N.J., Cruise M., Tam A., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015, 5(1):43-51.
12. Gatalica Z., Snyder C., Maney T., et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014, 23(12):2965-2970.
13. Le D.T., Uram J.N., Wang H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372(26):2509-2520.
14. Korabiowska M., Brinck U., Dengler H., Stachura J., Schauer A., Droese M. Analysis of the DNA repair protein expression in malignant melanoma. Anticancer Res 2000, 20(6B):4499-4505.
15. Lo Muzio L., Nocini P., Mignogna M.D., et al. Immunocytochemical detection of hMSH2 and hMLH1 expression in oral melanoma. Anticancer Res 2000, 20(2A):741-748.
16. Birindelli S., Tragni G., Bartoli C., et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2000, 86(2):255-261.
17. Peris K., Keller G., Chimenti S., Amantea A., Kerl H., Höfler H. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol 1995, 105(4):625-628.
18. Quinn A.G., Healy E., Rehman I., Sikkink S., Rees J.L. Microsatellite instability in human non-melanoma and melanoma skin cancer. J Invest Dermatol 1995, 104(3):309-312.
19. Richetta A., Silipo V., Calvieri S., et al. Microsatellite instability in primary and metastatic melanoma. J Invest Dermatol 1997, 109(1):119-120.
20. Talwalkar V.R., Scheiner M., Hedges L.K., Butler M.G., Schwartz H.S. Microsatellite instability in malignant melanoma. Cancer Genet Cytogenet 1998, 104(2):111-114.
21. Alvino E., Marra G., Pagani E., et al. High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol 2002, 118(1):79-86.
22. Hussein M.R. Genetic pathways to melanoma tumorigenesis. J Clin Pathol 2004, 57(8):797-801.
23. Hussein M.R., Sun M., Tuthill R.J., et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001, 28(7):343-350.
24. Palmieri G., Ascierto P.A., Cossu A., et al. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 2003, 13(2):167-170.
25. Palmieri G., Cossu A., Ascierto P.A., et al. Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. Br J Cancer 2000, 83(12):1707-1714.
26. Richetta A., Ottini L., Falchetti M., et al. Instability at sequence repeats in melanocytic tumours. Melanoma Res 2001, 11(3):283-289.
27. Tomlinson I.P., Beck N.E., Bodmer W.F. Allele loss on chromosome 11q and microsatellite instability in malignant melanoma. Eur J Cancer 1996, 32A(10):1797-1802.
28. Kroiss M.M., Vogt T.M., Schlegel J., Landthaler M., Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venereol 2001, 81(4):242-245.
29. Whitehall V.L., Walsh M.D., Young J., Leggett B.A., Jass J.R. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001, 61(3):827-830.
30. Kohonen-Corish M.R., Daniel J.J., Chan C., et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005, 23(10):2318-2324.
31. Kohonen-Corish M.R., Cooper W.A., Saab J., Thompson J.F., Trent R.J., Millward M.J. Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. J Invest Dermatol 2006, 126(1):167-171.
32. Young L.C., Thulien K.J., Campbell M.R., et al. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study. Carcinogenesis 2004, 25(10):1821-1827.
33. Runger T.M., Emmert S., Schadendorf D., Diem C., Epe B., Hellfritsch D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 2000, 114(1):34-39.
34. O'Brien V., Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006, 27(4):682-692.
35. Augustine C.K., Yoo J.S., Potti A., et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 2009, 15(2):502-510.
36. Honecker F., Wermann H., Mayer F., et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment- resistant germ cell tumors. J Clin Oncol 2009, 27(13):2129-2136.
37. Kamat N., Khidhir M.A., Hussain S., Alashari M.M., Rannug U. Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients. Cancer Cell Int 2014, 14(1):118.
38. Sobol R.W., Tawbi H., Jukic D.M., Mule R., Mascari R., Kirkwood J.M. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma. J Clin Oncol (Meeting Abstracts) 2006, 24(18S):8015.
39. Bradbury P.A., Middleton M.R. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004, 15(5):421-426.